In the news.
- 2026
The Hillman Letter launches on Substack
New publication on FDA regulatory strategy, frontier therapeutics, and capital decisions in healthcare. Read at thehillmanletter.substack.com.
- 2026
Hillman Ventures marks 30 years of frontier biotech investing
The private family office founded in Dallas in 1995 continues its focus on inflammation, damaged tissue, and tumor-based cancer platforms grounded in FDA biologics pathway thinking.
- 2026
FixCancer.org launches public-facing TOL site
Targeted Osmotic Lysis explainer and mechanism walkthrough goes live. TOL is investigational, is not FDA-approved, and has no registered clinical trial. See
fixcancer.org.
- Targeted Osmotic Lysis is investigational. It is not approved by the FDA for any indication, it has not been shown to be safe or effective in humans, and it is not available as a treatment. No clinical trial of it is registered on ClinicalTrials.gov.
Andrew Hillman Scholarship for Entrepreneurs
A scholarship in development to support undergraduate students with demonstrated entrepreneurial ambition. Details to be announced.
Andrew Hillman Grant for Biotech
A grant in development to support work at the intersection of biotechnology and translational medicine. Details to be announced.
For journalists.
Press kit
Verified bio at three lengths, fact sheet, speaking topics, headshots, downloads. Open the press kit.
Public record
The primary-source operating record and timeline at andrewhillmanrecord.com. Verified directly, no PR filter.
Direct contact
For interviews, press, podcasts, and quote requests: [email protected]. Direct response.
Topic depth
FDA biologics pathway, exosome regulatory science, family office structure, compliance, expert witness, Dallas biotech ecosystem.